• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利用治疗药物监测指导头孢他啶/阿维巴坦治疗产KPC的中枢神经系统感染

Using Therapeutic Drug Monitoring to Treat KPC-Producing Central Nervous System Infection With Ceftazidime/Avibactam.

作者信息

Yasmin Mohamad, Hanrahan Jennifer, Marshall Steven, Lodise Thomas P, Chen Liang, Perez Federico, Kreiswirth Barry, Bonomo Robert A

机构信息

Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.

Division of Infectious Diseases, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.

出版信息

Open Forum Infect Dis. 2020 Aug 18;7(9):ofaa349. doi: 10.1093/ofid/ofaa349. eCollection 2020 Sep.

DOI:10.1093/ofid/ofaa349
PMID:32964066
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7491706/
Abstract

This report describes the treatment of carbapenemase (KPC)-3-producing multidrug-resistant with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC- central nervous system infections.

摘要

本报告描述了一名发生神经外科术后脑膜炎和菌血症的产碳青霉烯酶（KPC）-3多重耐药患者使用头孢他啶/阿维巴坦（CAZ-AVI）的治疗情况。对脑脊液和血液样本进行的治疗药物监测显示，输注后最初60分钟内CAZ-AVI浓度水平比最低抑菌浓度高20倍，这为CAZ-AVI治疗KPC中枢神经系统感染的效用提供了证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d801/7491706/658865d6436d/ofaa349f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d801/7491706/658865d6436d/ofaa349f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d801/7491706/658865d6436d/ofaa349f0001.jpg

相似文献

1
Using Therapeutic Drug Monitoring to Treat KPC-Producing Central Nervous System Infection With Ceftazidime/Avibactam.利用治疗药物监测指导头孢他啶/阿维巴坦治疗产KPC的中枢神经系统感染
Open Forum Infect Dis. 2020 Aug 18;7(9):ofaa349. doi: 10.1093/ofid/ofaa349. eCollection 2020 Sep.
2
Utilizing Ceftazidime/Avibactam Therapeutic Drug Monitoring in the Treatment of Neurosurgical Meningitis Caused by Difficult-to-Treat Resistant and KPC-Producing Enterobacterales.利用头孢他啶/阿维巴坦治疗药物监测来治疗由难治性耐药及产KPC的肠杆菌科细菌引起的神经外科脑膜炎
Open Forum Infect Dis. 2023 Oct 19;10(11):ofad507. doi: 10.1093/ofid/ofad507. eCollection 2023 Nov.
3
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
4
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae.头孢他啶-阿维巴坦挽救治疗产碳青霉烯酶肺炎克雷伯菌引起的感染患者的疗效。
Clin Infect Dis. 2019 Jan 18;68(3):355-364. doi: 10.1093/cid/ciy492.
5
Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort.头孢他啶-阿维巴坦治疗产 KPC 肺炎克雷伯菌感染：单中心队列研究中与临床疗效相关的因素。
Int J Antimicrob Agents. 2020 Sep;56(3):106075. doi: 10.1016/j.ijantimicag.2020.106075. Epub 2020 Jul 3.
6
In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.头孢他啶-阿维巴坦与不同抗菌药物联合对产KPC肺炎克雷伯菌临床分离株的体外相互作用
Int J Infect Dis. 2017 Dec;65:1-3. doi: 10.1016/j.ijid.2017.09.017. Epub 2017 Sep 22.
7
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
8
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .头孢他啶-阿维巴坦对产碳青霉烯酶的. 的体外和体内杀菌活性。
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
9
Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing From Patients Without Ceftazidime-Avibactam Use History - A Multicenter Study in China.中国一项多中心研究：既往无头孢他啶-阿维巴坦使用史的产KPC菌株对头孢他啶-阿维巴坦的敏感性降低
Front Microbiol. 2020 Jun 23;11:1365. doi: 10.3389/fmicb.2020.01365. eCollection 2020.
10
Emergence of Ceftazidime- and Avibactam-Resistant Klebsiella pneumoniae Carbapenemase-Producing Pseudomonas aeruginosa in China.中国产碳青霉烯酶的铜绿假单胞菌中对头孢他啶和阿维巴坦耐药的肺炎克雷伯菌的出现。
mSystems. 2021 Dec 21;6(6):e0078721. doi: 10.1128/mSystems.00787-21. Epub 2021 Nov 2.

引用本文的文献

1
Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due to .氨曲南加头孢他啶-阿维巴坦用于治疗由……引起的神经外科术后脑膜炎。 （原文此处病因未完整给出）
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0017225. doi: 10.1128/aac.00172-25. Epub 2025 Jun 2.
2
Treatment of pediatric central nervous system infection caused by carbapenem-resistant with ceftazidime/avibactam, two cases report and literature review.用头孢他啶/阿维巴坦治疗耐碳青霉烯类引起的小儿中枢神经系统感染：两例报告及文献综述
Front Pharmacol. 2025 Feb 21;16:1532608. doi: 10.3389/fphar.2025.1532608. eCollection 2025.
3
Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children.

本文引用的文献

1
Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors.β-内酰胺酶抑制剂的药代动力学和药效学。
Pharmacotherapy. 2019 Feb;39(2):182-195. doi: 10.1002/phar.2210. Epub 2019 Jan 20.
2
Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report.头孢他啶/阿维巴坦用于耐碳青霉烯类肺炎克雷伯菌脑膜炎：一例病例报告。
J Antimicrob Chemother. 2018 Jan 1;73(1):254-256. doi: 10.1093/jac/dkx358.
3
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
头孢他啶-阿维巴坦治疗肿瘤患儿多重耐药鲍曼不动杆菌感染的经验
Braz J Infect Dis. 2025 Mar-Apr;29(2):104515. doi: 10.1016/j.bjid.2025.104515. Epub 2025 Feb 21.
4
Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant K. pneumoniae shunt-related ventriculitis: two case reports and review of the literature.美罗培南-巴波巴坦作为鞘内保留疗法治疗耐碳青霉烯类肺炎克雷伯菌分流相关脑室炎：两例病例报告及文献综述
Eur J Clin Microbiol Infect Dis. 2025 Jan;44(1):193-196. doi: 10.1007/s10096-024-04986-6. Epub 2024 Nov 12.
5
Ceftazidime-Avibactam for the Treatment of Central Nervous System Infection Caused by Pan Drug-Resistant Carbapenem-Resistant Klebsiella Pneumoniae: A Case Report.头孢他啶-阿维巴坦治疗全耐药碳青霉烯类耐药肺炎克雷伯菌引起的中枢神经系统感染：一例报告
Infect Drug Resist. 2024 Aug 12;17:3501-3506. doi: 10.2147/IDR.S465004. eCollection 2024.
6
A Difficult Case of Ventriculitis in a 40-Year-Old Woman with Acute Myeloid Leukemia.一名40岁急性髓系白血病女性患者的脑室炎疑难病例
Antibiotics (Basel). 2024 May 10;13(5):432. doi: 10.3390/antibiotics13050432.
7
Meropenem-Vaborbactam for the Treatment of Post-Neurosurgical Meningitis Caused by KPC Producer Klebsiella Pneumoniae: A Case Report and Review of the Literature.美罗培南-巴坦治疗由产KPC肺炎克雷伯菌引起的神经外科术后脑膜炎：一例报告及文献复习
Antibiotics (Basel). 2024 Apr 5;13(4):331. doi: 10.3390/antibiotics13040331.
8
Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam.舒巴坦-多利培南成功治疗耐碳青霉烯鲍曼不动杆菌脑膜炎
Clin Infect Dis. 2024 Oct 15;79(4):819-825. doi: 10.1093/cid/ciae210.
9
New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.用于治疗医院获得性中枢神经系统感染的新型抗生素
Antibiotics (Basel). 2024 Jan 7;13(1):58. doi: 10.3390/antibiotics13010058.
10
Utilizing Ceftazidime/Avibactam Therapeutic Drug Monitoring in the Treatment of Neurosurgical Meningitis Caused by Difficult-to-Treat Resistant and KPC-Producing Enterobacterales.利用头孢他啶/阿维巴坦治疗药物监测来治疗由难治性耐药及产KPC的肠杆菌科细菌引起的神经外科脑膜炎
Open Forum Infect Dis. 2023 Oct 19;10(11):ofad507. doi: 10.1093/ofid/ofad507. eCollection 2023 Nov.
多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
4
Pharmacokinetics of Ceftazidime-Avibactam in Two Patients With KPC-Producing Klebsiella pneumoniae Bacteremia and Renal Impairment.头孢他啶-阿维巴坦在两名产KPC肺炎克雷伯菌菌血症和肾功能损害患者中的药代动力学
Pharmacotherapy. 2016 Nov;36(11):e172-e177. doi: 10.1002/phar.1840. Epub 2016 Oct 31.
5
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.头孢他啶/阿维巴坦聚焦：耐多药革兰氏阴性菌感染的新选择。
J Antimicrob Chemother. 2016 Oct;71(10):2713-22. doi: 10.1093/jac/dkw239. Epub 2016 Jul 17.
6
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦：第二代β-内酰胺/β-内酰胺酶抑制剂组合
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
7
Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.头孢他啶和阿维巴坦在患有大腿或肺部感染的中性粒细胞减少小鼠中的药效学
Antimicrob Agents Chemother. 2015 Nov 2;60(1):368-75. doi: 10.1128/AAC.01269-15. Print 2016 Jan.
8
Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.β-内酰胺类与β-内酰胺酶抑制剂组合的药代动力学/药效学：氨曲南/阿维巴坦的一种新方法。
J Antimicrob Chemother. 2015 Sep;70(9):2618-26. doi: 10.1093/jac/dkv132. Epub 2015 May 29.
9
Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model.在中空纤维药效学模型中头孢他啶和阿维巴坦对产β-内酰胺酶肠杆菌科细菌的活性
Antimicrob Agents Chemother. 2014 Jun;58(6):3366-72. doi: 10.1128/AAC.00080-14. Epub 2014 Mar 31.
10
Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential.阿维巴坦在人体中的质量平衡恢复及代谢物谱评估与体外药物相互作用潜力
Drug Metab Dispos. 2014 May;42(5):932-42. doi: 10.1124/dmd.113.055335. Epub 2014 Mar 10.